You are here: Industry Insights > RNAi

News List

Alnylam and Sanofi close research phase of 2014's $700m RNAi rare disease partnership pharmafile
April 11, 2019
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 million partnership originally launched in 2014 to develop RNAi therapeutics for rare conditions.
Regeneron, Alnylam Ink RNAi Alliance contractpharma
April 09, 2019
To discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases
Dicerna agrees another gene-silencing deal, this time with Lilly pharmaphorum
December 18, 2018
Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.
Sirnaomics cleared to start first trial of RNAi lead in cancer fiercebiotech
August 20, 2018
Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct cancer, its first oncology indication.
OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics firstwordpharma
May 30, 2018
SUWON, South Korea, May 29, 2018 /PRNewswire/ -- OliX Pharmaceuticals Inc., a leading developer of RNA interference (RNAi) therapeutics (CEO: Dong-ki Lee, Ph.D.), announced that it received the Phase I clinical trial authorization (CTA) with its anti-scar
BI, Dicerna to develop RNAi therapeutics for liver disease pharmatimes
November 06, 2017
Boehringer Ingelheim has linked with US group Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases.
Alnylam soars on likely first RNAi treatment approval pharmafile
September 25, 2017
Revealing data from its treatment, patisran, for Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy, the results are strong enough to make the long wait for first treatment worthwhile.

Previous page 1 2 Next page